Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.57 |
| ▸ | MMP8 | P22894 | 4/20 | 0.44 |
| ▸ | MMP3 | P08254 | 2/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20522865 | 1.00 | OPRD1 (0.57) | OPRD1OPRM1OPRK1MMP8MMP3 | |
| SCHEMBL20522864 | 1.00 | OPRD1 (0.57) | OPRD1OPRM1OPRK1MMP8MMP3 | |
| SCHEMBL3998836 | 0.94 | OPRM1 (0.51) | OPRD1OPRM1OPRK1AGTR2ACE | |
| SCHEMBL16066324 | 0.84 | PTPN1 (0.50) | OPRD1OPRM1OPRK1MMP8MMP3 | |
| SCHEMBL23361203 | 0.83 | POLB (0.50) | OPRD1OPRM1OPRK1AGTR2ACE | |
| SCHEMBL20720152 | 0.83 | OPRD1 (0.47) | OPRD1OPRM1OPRK1AGTR2ACE | |
| SCHEMBL9849102 | 0.83 | POLB (0.50) | OPRD1OPRM1OPRK1AGTR2ACE | |
| SCHEMBL17433744 | 0.83 | ALDH1A1 (0.47) | OPRD1OPRM1OPRK1AGTR2ACE | |
| SCHEMBL7156807 | 0.83 | OPRD1 (0.47) | OPRD1OPRM1OPRK1AGTR2ACE | |
| SCHEMBL30254985 | 0.82 | PTPN1 (0.54) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| CN-110461829-B | Substituted isoquinoline derivatives as immunomodulators | 百时美施贵宝公司 | 2023-02-28 | — | — | CN | disclosed |
| US-11332468-B2 | Azaindole derivatives as Rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-05-17 | — | — | US | disclosed |
| EP-3728248-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-02-02 | — | — | EP | disclosed |
| US-20200392133-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-12-17 | — | — | US | disclosed |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190127358-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
| EP-2975023-B1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9969709-B2 | Guanidinobenzoic acid ester compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-15 | — | — | US | disclosed |
| US-20160031847-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-02-04 | — | — | US | disclosed |
| EP-2975023-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | Astellas Pharma Inc. (JP) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332468-B2 | Azaindole derivatives as Rho-kinase inhibitors | ROCK1, ROCK2, RHOA | OPRD1 3335/4885OPRM1 3726/4885OPRK1 2266/4885 |
| US-20160031847-A1 | GUANIDINOBENZOIC ACID ESTER COMPOUND | SERPINB1, REN, SPINT2 | OPRD1 3665/4885OPRM1 4280/4885OPRK1 2846/4885 |
| US-20190127358-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H4, FXR1, NR1H2 | OPRD1 402/4885OPRM1 317/4885OPRK1 391/4885 |
| US-20200392133-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | OPRD1 3335/4885OPRM1 3726/4885OPRK1 2266/4885 |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | NR1H4, FXR1, NR1H2 | OPRD1 402/4885OPRM1 317/4885OPRK1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.